The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Triplet combination of azacitidine, venetoclax & gilteritinib for patients with FLT3-mutated AML
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines updates results from a Phase I/II study evaluating the triplet combination of azacitidine, venetoclax and gilteritinib in patients with either relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) or newly diagnosed FLT3-mutated AML. In the R/R cohort, a high response rate was achieved, with an overall median survival of approximately six months. In the frontline setting, all patients responded to the regimen, with most patients achieving complete remission (CR). Many patients in the newly diagnosed cohort also achieved measurable residual disease (MRD) negativity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stemline Therapeutics: Research Funding; Takeda Oncology: Consultancy, Research Funding; Pfizer: Consultancy; Novartis: Consultancy; AstraZeneca: Consultancy; Astellas: Research Funding; Amgen: Consultancy, Honoraria.
